𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Diagnostic accuracy of progressive supranuclear palsy in the Society for Progressive Supranuclear Palsy Brain Bank

✍ Scribed by Keith A. Josephs; Dennis W. Dickson

Publisher
John Wiley and Sons
Year
2003
Tongue
English
Weight
81 KB
Volume
18
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Diagnostic accuracy has been addressed previously for Parkinson's disease in a brain bank collection, but accuracy of progressive supranuclear palsy (PSP) has not been addressed in a similar setting. Clinical and genetic features of pathologically confirmed cases of PSP were compared with misdiagnosed cases to determine ways to improve diagnostic accuracy. Medical records were reviewed for 180 cases sent to the Society of Progressive Supranuclear Palsy Brain Bank that had standardized neuropathologic evaluations as well as determination of apolipoprotein E and tau genotypes. Of the 180 cases studied, 137 had PSP and 43 had other pathologic diagnoses. Corticobasal degeneration (CBD), multiple system atrophy (MSA), and diffuse Lewy body disease (DLBD) accounted for 70% of the misdiagnosed cases. History of tremor, psychosis, dementia, and asymmetric findings were more frequent in misdiagnosed cases. The frequency of H1 tau haplotype (93 vs. 80%) and H1H1 genotype (86 vs. 66%) were significantly greater and APOE ϵ4 carrier state was significantly less (17 vs. 41 %) in PSP compared with misdiagnosed cases. Pathologic evaluation of clinically diagnosed PSP remains important for definitive diagnosis, and CBD, MSA, and DLBD are the disorders most likely to be misdiagnosed as PSP. Tremor, psychosis, early dementia, asymmetric findings, absence of H1 haplotype, and presence of APOE ϵ4 should raise questions about a diagnosis of PSP. © 2003 Movement Disorder Society

📜 SIMILAR VOLUMES

Mitochondrial impairment in the cerebell
Mitochondrial impairment in the cerebellum of the patients with progressive supranuclear palsy
✍ Larry C.H. Park; David S. Albers; Hui Xu; J. Gordon Lindsay; M. Flint Beal; Gary 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 134 KB

## Abstract Abnormalities in energy metabolism and oxidative stress accompany many neurodegenerative diseases, including progressive supranuclear palsy (PSP). Previously, we showed decreased activities of a mitochondrial enzyme complex, α‐ketoglutarate dehydrogenase complex (KGDHC), and marked incr

Efaroxan, an alpha-2 antagonist, in the
Efaroxan, an alpha-2 antagonist, in the treatment of progressive supranuclear palsy
✍ Prof. Olivier Rascol; Kasia Sieradzan; Hélène Peyro-Saint-Paul; Claire Thalamas; 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 413 KB

## Abstract We have tested, in a prospective randomized, double‐blind, placebo‐controlled, crossover, 12‐week study, the effects of 2 mg efaroxan, a potent alpha‐2 antagonist, given three times per day to 14 patients with progressive supranuclear palsy. Efaroxan did not induce any significant chang

What features improve the accuracy of th
What features improve the accuracy of the clinical diagnosis of progressive supranuclear palsy-parkinsonism (PSP-P)?
✍ David R Williams; Andrew J Lees 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 74 KB

## Abstract Progressive supranuclear palsy‐parkinsonism (PSP‐P) is a primary tauopathy characterised by neurofibrillary degeneration, which is frequently mistaken for Parkinson's disease (PD), multiple system atrophy (MSA), and vascular parkinsonism (VP) at presentation. The aim of this study was t

In vivo demonstration of microstructural
In vivo demonstration of microstructural brain pathology in progressive supranuclear palsy: A DTI study using TBSS
✍ Susanne Knake; Marcus Belke; Katja Menzler; Ulrich Pilatus; Karla M. Eggert; Wol 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 174 KB

## Abstract We investigated DTI changes, potentially indicating alterations of microstructure and brain tissue integrity in 13 patients with probable progressive supranuclear palsy (PSP, Richardson syndrome) at stage III or less and 10 age‐matched controls using a whole brain analysis of diffusion

Increased tau burden in the cortices of
Increased tau burden in the cortices of progressive supranuclear palsy presenting with corticobasal syndrome
✍ Yoshio Tsuboi; Keith A. Josephs; Bradley F. Boeve; Irene Litvan; Richard J. Case 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB

## Abstract The objective of this study is to better define the pathological characteristics of pathologically proven progressive supranuclear palsy (PSP) presenting with the corticobasal syndrome (CBS). PSP is characterized by early falls, vertical supranuclear ophthalmoplegia, and axial rigidity,

Accuracy of magnetic resonance parkinson
Accuracy of magnetic resonance parkinsonism index for differentiation of progressive supranuclear palsy from probable or possible Parkinson disease
✍ Maurizio Morelli; Gennarina Arabia; Maria Salsone; Fabiana Novellino; Laura Giof 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 260 KB

## Abstract ## Background: Combined measurements on conventional magnetic resonance imaging (MRI), such as midbrain area/pons area or magnetic resonance parkinsonism index (MRPI) (pons area/midbrain area × middle cerebellar peduncle width/superior cerebellar peduncle width), have been proposed as